Cargando…
Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis
Here, we report a novel antibody drug conjugate (ADC) with the humanized anti-CD26 monoclonal antibody YS110 and triptolide (TR-1). YS110 has an inhibitory activity against the CD26-positive tumor growth via the immunological and direct pathway, such as intra-nuclear transportation of CD26 and YS110...
Autores principales: | Hayashi, Mutsumi, Madokoro, Hiroko, Yamada, Koji, Nishida, Hiroko, Morimoto, Chikao, Sakamoto, Michiie, Yanagawa, Hiroshi, Yamada, Taketo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721810/ https://www.ncbi.nlm.nih.gov/pubmed/31398954 http://dx.doi.org/10.3390/cancers11081138 |
Ejemplares similares
-
A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition
por: Hayashi, Mutsumi, et al.
Publicado: (2016) -
CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
por: Nishida, Hiroko, et al.
Publicado: (2018) -
Nuclear Localization of CD26 Induced by a Humanized Monoclonal Antibody Inhibits Tumor Cell Growth by Modulating of POLR2A Transcription
por: Yamada, Kohji, et al.
Publicado: (2013) -
Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect
por: Yamada, Kohji, et al.
Publicado: (2009) -
P1369: HDAC INHIBITION INVOLVES CD26 EXPRESSION ON MULTIPLE MYELOMA CELLS VIA THE C-MYC/SP1-MEDIATED PROMOTER ACTIVATION AND OVERCOMES THERAPEUTIC RESISTANCE BY HUMANIZED ANTIBODY
por: Nishida, Hiroko, et al.
Publicado: (2023)